Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting

References

• Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
   Google Scholar
• Iqbal N. The burden of type 2 diabetes: strategies to prevent or delay onset. Vasc Health Risk Manag 2007;3:511-20
   PubMedGoogle Scholar
• Bourdel-Marchasson I, Berrut G. Caring the elderly diabetic patient with respect to concepts of successful aging and frailty. Diabetes Metab 2005;31 Spec No 2:5S13-5S9
   PubMed Web of Science ®Google Scholar
• Bourdel-Marchasson I, Schweizer A, Dejager S. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract (Minneap) 2011;39:7-21
   PubMedGoogle Scholar
• Byetta (exenatide) [package insert]. San Diego, CA, USA: Amylin Pharmaceuticals, Inc., 2010
   Google Scholar
• Robles GI, Singh-Franco D. A review of exenatide as adjunctive therapy in patients with type 2 diabetes. Drug Des Devel Ther 2009;3:219-40
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
   PubMed Web of Science ®Google Scholar
• Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29:2333-48
   PubMed Web of Science ®Google Scholar
• Davies MJ, Donnelly R, Barnett AH, et al. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metabol 2009;11:1153-62
   PubMed Web of Science ®Google Scholar
• Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009;32:762-8
   PubMed Web of Science ®Google Scholar
• Bunck MC, Diamant M, Eliasson B, et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010;33:1734-7
   PubMed Web of Science ®Google Scholar
• Bunck MC, Corner A, Eliasson B, et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010;212:223-9
   PubMed Web of Science ®Google Scholar
• Pencek R, Blickensderfer A, Li Y, et al. Clinical outcomes in patients with type 2 diabetes treated with exenatide twice daily or once weekly: retrospective analysis of pooled clinical data stratified by age and duration of diabetes. Abstract Number 1033-P. American Diabetes Association 71st Scientific Sessions. San Diego, CA, USA, 2011
   Google Scholar
• European Medicines Agency. EPAR summary for the public: Byetta. London: EMA, 2010
   Google Scholar
• Brixner DI, McAdam-Marx C, Ye X, et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metabol 2009;11:1122-30
   PubMed Web of Science ®Google Scholar
• Brixner DI, Said Q, Kirkness C, et al. Assessment of cardiometabolic risk factors in a national primary care electronic health record database. Value Health 2007;10(s1):S29-S36
   Web of Science ®Google Scholar
• Standards of medical care in diabetes – 2011. Diabetes Care 2011;34(Suppl 1):S11-61
   Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
   PubMed Web of Science ®Google Scholar
• LaLonde R. Evaluating the econometric evaluations of training programs. Am Econ Rev 1986;76:604-20
   Web of Science ®Google Scholar
• Dehejia RH, Wahba S. Propensity score-matching methods for nonexperimental causal studies. Rev Econ Stat 2002;84:151-61
   Web of Science ®Google Scholar
• Bremer JP, Jauch-Chara K, Hallschmid M, et al. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009;32:1513-17
   PubMed Web of Science ®Google Scholar
• Funnell MM. Overcoming barriers to the initiation of insulin therapy. Clinical Diabetes 2007;25:136-8
   Google Scholar
• Pawaskar M, Li Q, Hoogwerf BJ, et al. Metabolic outcomes of matched patient populations initiating exenatide bid versus insulin glargine in an ambulatory care setting. Diabetes Obes Metabol 2012 Feb 9 [Epub ahead of print]
   Google Scholar
• Gaebler JA, Schultz JF, Blickensderfer A, et al. PDB1 treatment patterns and outcomes among older exenatide BID users compared to insulin glargine users. Value Health 2011;14:A91
   Web of Science ®Google Scholar
• Secnik Boye K, Matza LS, Oglesby A, et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes 2006;4:80
   PubMed Web of Science ®Google Scholar
• Pawaskar M, Zagar A, Sugihara T, et al. Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis. J Med Econ 2011;14:16-27
   PubMedGoogle Scholar
• Misurski D, Lage MJ, Fabunmi R, et al. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine. Appl Health Econ Health Policy 2009;7:245-54
   PubMedGoogle Scholar